LS
BEAM icon

Leelyn Smith’s Beam Therapeutics BEAM Stock Holding History

Leelyn Smith’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-215
Closed -$8.41K – 138
2022
Q4 		$8.41K Hold
215
– – ﹤0.01% 335
2022
Q3 		$10K Hold
215
– – ﹤0.01% 282
2022
Q2 		$8K Buy
+215
New +$8.55K ﹤0.01% 301

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Leelyn Smith's BEAM Position: Q1 2023 in Review

Leelyn Smith sold out of Beam Therapeutics (BEAM) in Q1 2023, closing a stake of 215 shares — an estimated $8.41K sold.

Leelyn Smith first reported a position in BEAM in Q2 2022 and held it in 3 quarters. The position peaked at $10K in Q3 2022. 206 funds tracked by Wall St. Rank hold BEAM as of Q1 2023.

  • Leelyn Smith reported no remaining Beam Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Leelyn Smith sold 215 Beam Therapeutics shares in Q1 2023, an estimated $8.41K.
  • Leelyn Smith first reported a position in Beam Therapeutics in Q2 2022 and held it in 3 quarters.
  • Leelyn Smith's Beam Therapeutics position peaked at $10K in Q3 2022.
  • 206 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2023.

Based on Leelyn Smith's 13F filing for Q1 2023, filed 12 May 2023.